Ivan Gergel - Nektar Therapeutics President

NKTR Stock  USD 0.93  0.04  4.49%   

President

Dr. Ivan P. Gergel, M.D., is Senior Vice President Drug Development Chief Medical Officer of the Company. Dr. Gergel served as Executive Vice President, Research Development and Chief Scientific Officer of Endo Pharmaceuticals, a pharmaceutical company. Prior to joining Endo Pharmaceuticals, he was Senior Vice President of Scientific Affairs and President of the Forest Research Institute of Forest Laboratories Inc. Prior to that, Dr. Gergel served as Vice President and Chief Medical Officer at Forest and Executive Vice President of the Forest Research Institute. He joined Forest in 1998 as Executive Director of Clinical Research following nine years at SmithKline Beecham, and was named Vice President of Clinical Development and Clinical Affairs in 1999. Dr. Gergel is a member of the Board of Directors of Corium International, Inc., a commercialstage biopharmaceutical company since 2014.
Age 56
Tenure 10 years
Professional MarksMBA
Address 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158
Phone415 482 5300
Webhttps://www.nektar.com
Gergel received his M.D. from the Royal Free Medical School of the University of London and an MBA from the Wharton School.

Nektar Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.1525) % which means that it has lost $0.1525 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1095) %, meaning that it created substantial loss on money invested by shareholders. Nektar Therapeutics' management efficiency ratios could be used to measure how well Nektar Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/29/2024, Return On Capital Employed is likely to grow to -0.38. In addition to that, Return On Assets is likely to grow to -0.66. At this time, Nektar Therapeutics' Total Assets are relatively stable compared to the past year. As of 03/29/2024, Non Currrent Assets Other is likely to grow to about 8.3 M, while Other Assets are likely to drop slightly above 2.5 M.
The company currently holds 230.4 M in liabilities with Debt to Equity (D/E) ratio of 0.33, which is about average as compared to similar companies. Nektar Therapeutics has a current ratio of 7.0, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Nektar Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Nektar Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nektar Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nektar to invest in growth at high rates of return. When we think about Nektar Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Monique MathesonNike Inc
57
Kevin PageWabash National
62
Mark BarrettAmerican Axle Manufacturing
55
Revital AvrahamiShagrir Group Vehicle
47
Mike PettitWabash National
N/A
Chris AbstonNike Inc
54
Allan BrazierAptiv PLC
57
Gregory DevesonAmerican Axle Manufacturing
58
David AyreNike Inc
56
Mariya TrickettAptiv PLC
38
Neil BoehmGentex
52
Mark WeberWabash National
44
Steve DowningGentex
37
Donald JosephAmerican Axle Manufacturing
60
Susan SuverAptiv PLC
57
Matthew FriendNike Inc
45
Jeanne JacksonNike Inc
64
Jerome DorlackAptiv PLC
36
Angelo LabbadiaEastern Co
66
Haim LeibovichShagrir Group Vehicle
46
Itzhak GolShagrir Group Vehicle
41
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California. Nektar Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 740 people. Nektar Therapeutics (NKTR) is traded on NASDAQ Exchange in USA. It is located in 455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158 and employs 137 people. Nektar Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Nektar Therapeutics Leadership Team

Elected by the shareholders, the Nektar Therapeutics' board of directors comprises two types of representatives: Nektar Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nektar. The board's role is to monitor Nektar Therapeutics' management team and ensure that shareholders' interests are well served. Nektar Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nektar Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Jonathan Zalevsky, Senior Vice President - Research , Chief Scientific Officer
Mark Wilson, Chief Sec
Lutz Lingnau, Independent Director
Roy Whitfield, Independent Director
Scott Greer, Independent Director
Mary Tagliaferri, Senior Vice President - Clinical Development and Chief Medical Officer
Christopher Kuebler, Independent Director
Karin Eastham, Independent Director
Jeff Ajer, Independent Director
Maninder Hora, Senior Vice President - Pharmaceutical Development and Manufacturing Operations
Brian MD, Chief Officer
Robert Chess, Independent Chairman of the Board
Wei Lin, Senior Vice President - Clinical Development and Head of Nektar's Oncology Programs
Dennis Winger, Independent Director
Vivian Wu, Director Affairs
Jennifer Ruddock, Vice President - Investor Relations and Corporate Affairs
Sandra Gardiner, Interim Officer
Kevin Brodbeck, VP Operations
Joseph Krivulka, Independent Director
Gilbert Labrucherie, Senior Vice President General Counsel, Secretary
John Nicholson, CFO and Sr. VP
Stephen Doberstein, Chief Scientific Officer and Sr. VP
Howard Robin, CEO and President and Director
Ivan Gergel, Senior Vice President - Drug Development & Chief Medical Officer
MD LAc, Chief Officer
John Northcott, Strategic Advisor
Loui Madakamutil, VP Research
Robert Bacci, Senior Operations
Susan Wang, Independent Director
Jillian Thomsen, Chief Accounting Officer and Sr. VP of Fin.

Nektar Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nektar Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Nektar Therapeutics Investors Sentiment

The influence of Nektar Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Nektar. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Nektar Therapeutics' public news can be used to forecast risks associated with an investment in Nektar. The trend in average sentiment can be used to explain how an investor holding Nektar can time the market purely based on public headlines and social activities around Nektar Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Nektar Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Nektar Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Nektar Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Nektar Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Nektar Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Nektar Therapeutics' short interest history, or implied volatility extrapolated from Nektar Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Nektar Therapeutics is a strong investment it is important to analyze Nektar Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nektar Therapeutics' future performance. For an informed investment choice regarding Nektar Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nektar Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in Nektar Stock, please use our How to Invest in Nektar Therapeutics guide.
You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Nektar Stock analysis

When running Nektar Therapeutics' price analysis, check to measure Nektar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nektar Therapeutics is operating at the current time. Most of Nektar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Nektar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nektar Therapeutics' price. Additionally, you may evaluate how the addition of Nektar Therapeutics to your portfolios can decrease your overall portfolio volatility.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Is Nektar Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nektar Therapeutics. If investors know Nektar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nektar Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.45)
Revenue Per Share
0.474
Quarterly Revenue Growth
0.085
Return On Assets
(0.15)
Return On Equity
(1.11)
The market value of Nektar Therapeutics is measured differently than its book value, which is the value of Nektar that is recorded on the company's balance sheet. Investors also form their own opinion of Nektar Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Nektar Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nektar Therapeutics' market value can be influenced by many factors that don't directly affect Nektar Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nektar Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Nektar Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nektar Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.